What is NDC 50881-010?

50881-010 is the product NDC for Jakafi (ruxolitinib), Ruxolitinib 10 mg/1 tablet, listed with the FDA by Incyte Corporation. It has 2 package NDCs, shown above in 10- and 11-digit form.

Incyte Corporation, NDC labeler code 50881. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Jakafi?

4 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Jakafi NDC 50881-010 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)50881-010Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50881-0010Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50881-010-01	50881001001	28 TABLET in 1 BOTTLE, PLASTIC (50881-010-01)Marketed from Nov 16, 2011
50881-010-60	50881001060	60 TABLET in 1 BOTTLE, PLASTIC (50881-010-60)Marketed from Nov 16, 2011

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Jakafi
Generic name (nonproprietary): ruxolitinib
Active ingredients: Ruxolitinib — 10 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Incyte CorporationNDC labeler code 50881
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 202192
Marketing start: Nov 16, 2011
Listing expires: Dec 31, 2027
Other FDA classes: Janus Kinase Inhibitors (Mechanism)
Identifiers: Product ID 50881-010_1c261eb0-f426-47a1-8281-62282d207644SPL ID 1c261eb0-f426-47a1-8281-62282d207644SPL set ID f1c82580-87ae-11e0-bc84-0002a5d5c51bRxCUI 1193331, 1193337, 1193339, 1193341, 1193343, 1193345, 1193347, 1193349, 1193351, 1193353, 2743012, 2743016, 2743019, 2743022, 2743025, 2743028, 2743032, 2743035, 2743041, 2743044UNII 82S8X8XX8HUPC 0350881015601, 0350881055089, 0350881022081, 0350881010606, 0350881005602, 0350881025600, 0350881011085, 0350881033087, 0350881020605, 0350881044083
Pharmacologic class: Janus Kinase Inhibitor; Kinase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450881001001 followed by a unit qualifier and the quantity

Package 50881-0010-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 20, 2026.

Indications (excerpt from the label)

JAKAFI/JAKAFI XR is a kinase inhibitor indicated for treatment of: intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults. ( 1.1 ) polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea. ( 1.2 ) steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. ( 1.3 ) chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. ( 1.4 ) 1.1 Myelofibrosis JAKAFI/JAKAFI XR is indicated for treatment of intermediate or high…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 50881-010

What is NDC 50881-010?: 50881-010 is the product NDC for Jakafi (ruxolitinib), Ruxolitinib 10 mg/1 tablet, listed with the FDA by Incyte Corporation. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Jakafi (Ruxolitinib).
What is the active ingredient?: Ruxolitinib.
Who is the labeler?: Incyte Corporation, NDC labeler code 50881. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Jakafi?: 4 other product NDCs are listed under this name. See all Jakafi NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Jakafi NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Jakafiruxolitinib	Ruxolitinib 5 mg/1	TabletOral	Incyte Corporation	50881-005	50881-0005-60
Jakafiruxolitinib	Ruxolitinib 15 mg/1	TabletOral	Incyte Corporation	50881-015	50881-0015-60
Jakafiruxolitinib	Ruxolitinib 20 mg/1	TabletOral	Incyte Corporation	50881-020	50881-0020-60
Jakafiruxolitinib	Ruxolitinib 25 mg/1	TabletOral	Incyte Corporation	50881-025	50881-0025-60

Other NDCs under NDA 202192

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 202192
Product	Strength	Form · route	Labeler	Product NDC
Jakafiruxolitinib	Ruxolitinib 5 mg/1	TabletOral	Incyte Corporation	50881-005
Jakafiruxolitinib	Ruxolitinib 20 mg/1	TabletOral	Incyte Corporation	50881-020
Jakafiruxolitinib	Ruxolitinib 15 mg/1	TabletOral	Incyte Corporation	50881-015
Jakafiruxolitinib	Ruxolitinib 25 mg/1	TabletOral	Incyte Corporation	50881-025

Jakafi (Ruxolitinib) NDC 50881-010

NDC codes

Product information

Billing references

Product label

About NDC 50881-010

Other NDCs under NDA 202192

Keep searching with a free account

NDC codes

Product information

Billing references

Product label

About NDC 50881-010

Related NDCs: other Jakafi products

Other NDCs under NDA 202192